Literature DB >> 33237764

Rationally Designed Redox-Active Au(I) N-Heterocyclic Carbene: An Immunogenic Cell Death Inducer.

Sajal Sen1, Stephanie Hufnagel2, Esther Y Maier3, Isaiah Aguilar1, Jayaraman Selvakumar4, Jennie E DeVore3, Vincent M Lynch1, Kuppuswamy Arumugam4, Zhengrong Cui2, Jonathan L Sessler1, Jonathan F Arambula1.   

Abstract

Immunogenic cell death (ICD) is a way of reengaging the tumor-specific immune system. ICD can be induced by treatment with chemotherapeutics. However, only a limited number of drugs and other treatment modalities have been shown to elicit the biomarker responses characteristic of ICD and to provide an anticancer benefit in vivo. Here, we report a rationally designed redox-active Au(I) bis-N-heterocyclic carbene that induces ICD both in vitro and in vivo. This work benefits from a synthetic pathway that allows for the facile preparation of asymmetric redox-active Au(I) bis-N-heterocyclic carbenes.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33237764      PMCID: PMC9398512          DOI: 10.1021/jacs.0c09753

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   16.383


  38 in total

Review 1.  Anticancer metal drugs and immunogenic cell death.

Authors:  Alessio Terenzi; Christine Pirker; Bernhard K Keppler; Walter Berger
Journal:  J Inorg Biochem       Date:  2016-06-16       Impact factor: 4.155

2.  Expanding the biological utility of bis-NHC gold(i) complexes through post synthetic carbamate conjugation.

Authors:  Sajal Sen; Yue Li; Vincent Lynch; Kuppuswamy Arumugam; Jonathan L Sessler; Jonathan F Arambula
Journal:  Chem Commun (Camb)       Date:  2019-08-29       Impact factor: 6.222

3.  Immunogenic death of colon cancer cells treated with oxaliplatin.

Authors:  A Tesniere; F Schlemmer; V Boige; O Kepp; I Martins; F Ghiringhelli; L Aymeric; M Michaud; L Apetoh; L Barault; J Mendiboure; J-P Pignon; V Jooste; P van Endert; M Ducreux; L Zitvogel; F Piard; G Kroemer
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

Review 4.  Immunotherapeutic approaches for small-cell lung cancer.

Authors:  Wade T Iams; Jason Porter; Leora Horn
Journal:  Nat Rev Clin Oncol       Date:  2020-02-13       Impact factor: 66.675

Review 5.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

Review 6.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

7.  High levels of thioredoxin reductase 1 modulate drug-specific cytotoxic efficacy.

Authors:  Sofi E Eriksson; Stefanie Prast-Nielsen; Emilie Flaberg; Laszlo Szekely; Elias S J Arnér
Journal:  Free Radic Biol Med       Date:  2009-09-17       Impact factor: 7.376

Review 8.  Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

Authors:  Laurence Zitvogel; Lorenzo Galluzzi; Mark J Smyth; Guido Kroemer
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

9.  Gold(I)-Catalyzed Formation of Naphthalene/Acenaphthene Heterocyclic Acetals.

Authors:  Malina Michalska; Krzysztof Grudzień; Paweł Małecki; Karol Grela
Journal:  Org Lett       Date:  2018-02-07       Impact factor: 6.005

10.  Understanding and predicting the potency of ROS-based enzyme inhibitors, exemplified by naphthoquinones and ubiquitin specific protease-2.

Authors:  Pushparathinam Gopinath; Atif Mahammed; Shimrit Ohayon; Zeev Gross; Ashraf Brik
Journal:  Chem Sci       Date:  2016-08-05       Impact factor: 9.825

View more
  8 in total

Review 1.  Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future.

Authors:  Sajal Sen; Miae Won; Matthew S Levine; Yuvin Noh; Adam C Sedgwick; Jong Seung Kim; Jonathan L Sessler; Jonathan F Arambula
Journal:  Chem Soc Rev       Date:  2022-02-21       Impact factor: 60.615

2.  Detailed structural and spectroscopic elucidation of ferrocenium coupled N-heterocyclic carbene gold(I) complexes.

Authors:  Garrett L Reinhard; Selvakumar Jayaraman; Joshua W Prybil; Jonathan F Arambula; Kuppuswamy Arumugam
Journal:  Dalton Trans       Date:  2022-01-25       Impact factor: 4.569

3.  Mecheliolide elicits ROS-mediated ERS driven immunogenic cell death in hepatocellular carcinoma.

Authors:  Zhongren Xu; Jianqiang Xu; Shibo Sun; Wei Lin; Yongming Li; Qiuyue Lu; Fuwei Li; Zhibin Yang; Yunlong Lu; Wukun Liu
Journal:  Redox Biol       Date:  2022-05-28       Impact factor: 10.787

4.  Dual-Channel Fluorescent Probe for the Simultaneous Monitoring of Peroxynitrite and Adenosine-5'-triphosphate in Cellular Applications.

Authors:  Luling Wu; Jihong Liu; Xue Tian; Robin R Groleau; Beidou Feng; Yonggang Yang; Adam C Sedgwick; Hai-Hao Han; Yang Wang; Han-Min Wang; Fang Huang; Steven D Bull; Hua Zhang; Chusen Huang; Yi Zang; Jia Li; Xiao-Peng He; Ping Li; Bo Tang; Tony D James; Jonathan L Sessler
Journal:  J Am Chem Soc       Date:  2021-12-21       Impact factor: 15.419

Review 5.  Immunogenic Cell Death Induction by Ionizing Radiation.

Authors:  Mengqin Zhu; Mengdie Yang; Jiajia Zhang; Yuzhen Yin; Xin Fan; Yu Zhang; Shanshan Qin; Han Zhang; Fei Yu
Journal:  Front Immunol       Date:  2021-08-20       Impact factor: 7.561

6.  Profile of Jonathan L. Sessler.

Authors:  Sandeep Ravindran
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 12.779

7.  Elucidation of Structure-Activity Relationships in Indolobenzazepine-Derived Ligands and Their Copper(II) Complexes: the Role of Key Structural Components and Insight into the Mechanism of Action.

Authors:  Irina Kuznetcova; Felix Bacher; Samah Mutasim Alfadul; Max Jing Rui Tham; Wee Han Ang; Maria V Babak; Peter Rapta; Vladimir B Arion
Journal:  Inorg Chem       Date:  2022-06-17       Impact factor: 5.436

Review 8.  Organometallic gold(I) and gold(III) complexes for lung cancer treatment.

Authors:  Juzheng Zhang; Yanping Li; Ronghao Fang; Wei Wei; Yong Wang; Jiamin Jin; Feng Yang; Jian Chen
Journal:  Front Pharmacol       Date:  2022-09-13       Impact factor: 5.988

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.